metabolic · fda-approved
Tirzepatide
Agonista dual GIP/GLP-1.
Status:fda-approved
Updated:May 13, 2026
Contributors:2
Half-life
120 h
Routes
SC
Typical dose
2500–15000 mcg
Mechanism of action
Ativação cruzada GIP+GLP-1 para sinergia metabólica.
Reported applications
- · glycemic control
- · weight management
Frequently asked
What is Tirzepatide?
Agonista dual GIP/GLP-1.
What is the half-life of Tirzepatide?
Reference half-life: approximately 120 hours. Individual pharmacokinetics may vary.
Is PX7 prescribing Tirzepatide?
No. PX7 is an educational reference and a community knowledge layer. It does not prescribe, sell, or recommend substances.
Explore the cluster
PX7 publishes educational and community-curated references on regenerative and longevity science. Nothing on this page is medical advice, prescription, or a recommendation to obtain or use any substance. Always consult a qualified clinician.